• 1
    Foster PA, Fulcher CA, Marti T, Titani K, Zimmerman TS. A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor. J Biol Chem 1987; 262: 84436.
  • 2
    Hilbert L, Jorieux S, Proulle V, Favier R, Goudemand J, Parquet A, Meyer D, Fressinaud E, Mazurier C and the INSERM Network on molecular abnormalities in von Willebrand disease. Two novel mutations, Q1053H and C1060R, located in the D3 domain of von Willebrand factor, are responsible for decreased FVIII-binding capacity. Br J Haematol 2003; 120: 62732.DOI: 10.1046/j.1365-2141.2003.04163.x
  • 3
    Allen S, Abuzenadah AM, Blagg JL, Hinks J, Nesbitt IM, Goodeve AC, Gursel T, Ingerslev J, Peake IR, Daly ME. Two novel type 2N von Willebrand disease-causing mutations that result in defective factor VIII binding, multimerization, and secretion of von Willebrand factor. Blood 2000; 95: 20007.
  • 4
    Jorieux S, Fressinaud E, Goudemand J, Gaucher C, Meyer D, Mazurier C and the INSERM Network on Molecular Abnormalities in von Willebrand disease. Conformational changes in the D' domain of von Willebrand factor induced by Cys 25 and Cys 95 mutations lead to factor VIII binding defect and multimeric impairment. Blood 2000; 95: 313945.
  • 5
    Hilbert L, Gaucher C, Mazurier C. Identification of two mutations (Arg611Cys and Arg611His) in the A1 loop of von Willebrand factor (vWF) responsible for type 2 von Willebrand disease with decreased platelet-dependent function of vWF. Blood 1995; 86: 10108.